Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Nov 30;10:20876. doi: 10.1038/s41598-020-77947-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Overview and immunoglobulin response after VitD3-supplemented GP-SCIT. (a) Experimental protocol. (b) Treatment groups. (c) Serum total IgE (ng/mL) taken before SCIT (white bars, Pre1), after SCIT (grey bars, Pre2), and after challenges (black bars, Post). (d) GP-spIgE (Arbitrary Units (AU)/mL, Pre1-2, Post). (e) GP-spIgG1 (AU/mL, Pre1-2, Post). (f) GP-spIgG2a (AU/mL, Pre1-2, Post). (g) Neutralizing activity plotted as ratio of GP-spIgG1/GP-spIgE in Post sera. (h) Neutralizing activity of GP-spIgG2a/GP-spIgE. (i) Fold induction of GP-spIgE after challenge (Post-sera/Pre2-sera). (c–f) mean ± SEM (n = 8). (g–i) Box-and-whiskers plots (min–max). NC negative control, PBS challenged; PC positive control, GP challenged; PCS PC with 300 nmol SAINT; PCD PC with 300 ng VitD3 in SCIT; GP 300kSQ GP in SCIT; GPS 300kSQ + 300 nmol SAINT; GPD 300kSQ + 300 ng VitD3; GP100DS 300kSQ + 100 ng VitD3 + 300 nmol SAINT; GP300DS 300kSQ + 300 ng VitD3 + 300 nmol SAINT. *P < 0.05, **P < 0.01, ***P < 0.001 compared to their own matching controls, unless otherwise specified.